The FDA says a professional journal ad for Pfizer’s antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.
From the October 01, 2007 Issue of MM+M - Medical Marketing and Media
